Drug Development
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
FEATURED STORIES
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.
With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Ohio-based Forge Biologics secured $120 million in a Series B financing round to support the clinical development of its gene therapy program for rare diseases, including the typically fatal Krabbe disease.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Moderna, one of three companies to have a COVID-19 vaccine authorized in the U.S., isn’t resting on its accomplishments but is instead working to scale up production further and improve on its vaccine.
Novartis AG Chief Executive Officer Vas Narasimhan believes that the hybrid of remote and on-site office work is the future.
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
Pfizer is expanding its presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and its lead antifungal compound Fosmanogepix.
According to Teo, the definition of the next pandemic depends a lot on one’s perspective.
Top-line results from the Phase III INVIGORATE trial show Aldeyra Therapeutics’, reproxalap, significantly reduced ocular itching in patients with allergic conjunctivitis.
As vaccinations against COVID-19 continue across the U.S., there appears to be an increase in cases in younger populations.
Galectin Therapeutics takes its role seriously, as perhaps the only company developing a therapy for non-alcoholic steatohepatitis (NASH) cirrhosis, an advanced form of NASH. Along with its Phase IIb/III clinical trial, it recently launched NAVIGATEnash.com.